Price
No data yet.
Social Signal Score
Analyst Ratings
4 analystsRevenue
$3.70B+1908.46%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gilles G. Martin
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 65,694
- Beta
- 0.86
- Country
- LU
- Piotroski score
- 6 / 9 (Middling)
- Altman Z-score
- 3.34
Financials
Revenue
$3.70B+1908.5%Net Income
$301.55M+3344.7%EBITDA
$795.81M+2686.1%Free Cash Flow
$383.43M+16937.3%EPS (diluted)
$1.63+2616.7%Shares Outstanding (diluted)
183.70M+23.0%Operating Expenses
$0.00Cash & Debt
$617.07MReturn of Capital
$333.50MDividend per Share
$0.84Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $7.29B | $474.82M | $2.64 |
| 2024 | $6.95B | $406.40M | $2.13 |
| 2023 | $6.51B | $310.20M | $1.57 |
| 2022 | $6.71B | $610.20M | $3.17 |
| 2021 | $6.72B | $782.60M | $4.09 |
| 2020 | $5.44B | $539.40M | $2.90 |
| 2019 | $4.56B | $195.20M | $1.10 |
| 2018 | $3.78B | $223.90M | $1.26 |
| 2017 | $2.97B | $216.77M | $1.05 |
| 2016 | $2.54B | $174.00M | $0.87 |
| 2015 | $1.95B | $87.32M | $0.57 |
| 2014 | $1.41B | $79.10M | $0.52 |
| 2013 | $1.23B | $72.18M | $0.35 |
| 2012 | $1.04B | $65.92M | $0.37 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from ERFSF's reported EPS growth of 16.3% a year over 13 years.
- EPS in 5 years
- $5.61
- Implied price
- $134.70
- Return from $82.88
- 10.2% a year
To earn 15.0% a year on these assumptions you'd need to buy at $66.97 — -19.2% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 16 | 20 | 24 | 28 | 32 |
|---|---|---|---|---|---|
| 6.3% | -7.1% | -2.9% | 0.7% | 3.9% | 6.7% |
| 11.3% | -2.8% | 1.7% | 5.5% | 8.8% | 11.7% |
| 16.3% | 1.6% | 6.3% | 10.2% | 13.7% | 16.7% |
| 21.3% | 6.0% | 10.8% | 14.9% | 18.5% | 21.7% |
| 26.3% | 10.4% | 15.4% | 19.7% | 23.4% | 26.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsbusinesswire.com·19h ago·Neutral
Eurofins Scientific: Director/PDMR Shareholding LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATE
View source ↗ - Newsbusinesswire.com·3d ago·Neutral
Eurofins Scientific SE: Director/PDMR Shareholding LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCI
View source ↗ - Newsbusinesswire.com·6d ago·Neutral
Eurofins Scientific: Director/PDMR Shareholding LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATE
View source ↗ - Newsbusinesswire.com·28d ago·Neutral
Eurofins Scientific: Director/PDMR Shareholding LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATE
View source ↗ - Newsbusinesswire.com·42d ago·Neutral
Eurofins Scientific SE: Director/PDMR Shareholding LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCI
View source ↗ - Newsbusinesswire.com·54d ago·Neutral
Eurofins Scientific: Director/PDMR Shareholding LUXEMBOURG--(BUSINESS WIRE)--Eurofins Scientific SE (EUFI.PA) has received various notifications of dealing from Persons Discharging Managerial Responsibilities (“PDMR”). The notification of Dealing Form for each PDMR can be found below. This notification is made in accordance with the European Market Abuse Regulation. NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATE
View source ↗
Earnings
Tue, Mar 2(in 5 months)
Consensus estimate $1.82 per share
Typical surprise +1.4% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Jul 23$2.39 vs $2.18beat
- Thu, Jan 29$1.50 vs $1.48beat
- Wed, Jul 23$1.93 vs $2.01miss
- Thu, Jan 30$1.39 vs $1.54miss
- Wed, Jul 24$1.76 vs $1.59beat
- Tue, Feb 27$0.95 vs $1.32miss
Estimates and results for ERFSF via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
No disclosed congressional trades in ERFSF.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.